CheckMyRecalls

Slate Run Pharmaceuticals recalls Eptifibatide Injection

Published
4 Mar 2026
Units affected
N/A
Agency
FDA
Country
United States

The hazard

Labeling: Not Elsewhere Classified. The carton for Eptifibatide Injection 75 mg/100 mL states 75 mg/100 mL vial for weight-adjusted bolus dosing. The approved statement is 75 mg/100 mL vial for weight-adjusted infusion.

Classification: Class III — this product is unlikely to cause health problems but breaks FDA rules (for example labeling).

What to do

Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.

  • Check the lot number on the box or bottle.
  • Talk to your pharmacist or doctor before stopping any prescribed medicine.
  • Return the product to the pharmacy for safe disposal.
Read the official FDA notice

Product details

Eptifibatide Injection, 75 mg/100 mL vial for weight-adjusted bolus dosing, 1x100 mL Single-dose Vial, For Intravenous Use Only, Rx Only, Manufactured by: Hainan Poly Pharm. Co., Ltd., Guilinyang Economic Development Area, Haikou, Hainan Province, China 571127; Distributed by: Slate Run Pharmaceuticals, LLC, Columbus, Ohio 43215. NDC Slate Run Carton Label: 70436-027-80; NDC ProRx Carton Label: 70436-163-80

Brand / company
Slate Run Pharmaceuticals
Codes / lots
All lots within expiry
Distribution
Nationwide within the USA.
Recall status
Ongoing

Source: U.S. Food and Drug Administration, published 4 Mar 2026. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.